- Home
- ANGO vs PACB Comparison
ANGO vs PACB Comparison
Compare ANGO & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGO | PACB |
|---|---|---|
| Founded | 1988 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.2M | 419.8M |
| IPO Year | 2004 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ANGO | PACB |
|---|---|---|
| Price | $10.47 | $1.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $18.00 | $1.83 |
| AVG Volume (30 Days) | 472.7K | ★ 5.4M |
| Earning Date | 04-02-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.92 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $291,010,000.00 | $93,468,000.00 |
| Revenue This Year | $9.11 | $11.32 |
| Revenue Next Year | $4.94 | $12.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.17 | 3.04 |
| 52 Week Low | $8.36 | $0.85 |
| 52 Week High | $13.99 | $2.73 |
Technical Indicators
Market Signals| Indicator | ANGO | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 48.66 | 58.09 |
| Support Level | $10.38 | $1.52 |
| Resistance Level | $11.25 | $1.64 |
| Average True Range (ATR) | 0.60 | 0.10 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 42.50 | 91.67 |
Price Performance
Historical ComparisonAbout ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.